Eli Lilly selected Huntsville, Alabama, as the site for a $6 billion active pharmaceutical ingredient (API) facility that will produce peptide and small‑molecule APIs, including the oral GLP‑1 candidate orforglipron. Lilly said construction will begin in 2026 with completion targeted for 2032 and that the investment will create 450 permanent roles plus thousands of construction jobs. The Huntsville site is the third of four large U.S. mega‑sites Lilly announced under a $27 billion manufacturing expansion plan and follows earlier selections in Houston and near Richmond, Virginia. Lilly cited regional workforce and proximity to the HudsonAlpha Institute for Biotechnology as factors in the location choice. The move underscores Big Pharma’s push to onshore critical drug‑substance capacity amid supply‑chain scrutiny and rising demand for GLP‑1 therapies. Companies developing oral obesity medicines and suppliers of raw materials should reassess capacity and partnership opportunities as large vertical investments enter the market.